The different responses to ICI therapy for CRC patients with or without KRAS mutation are mainly associated with factors of TIME, especially CD56bright NK cells, which suggested that the clinical benefit of ICIs for CRC patients with KRAS could be well improved through the regulation of NK cells, especially, CD56bright NK cells. This evidence concerns the gene KRAS and colorectal carcinoma.